Drug Trial Radar · NCT07400107
AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
985
Actual
Start
May 20, 2026
Primary completion
Dec 19, 2028
Study completion Dec 19, 2028
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Feb 10, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight and type 2 diabetes. Participant will receive 2 injections every week: an active medicine and a placebo, both taken as injections under the skin once a week. The placebo is a treatment with no active medicine in it and will be given to all participants. In addition to placebo, participants will receive either of the active medicine NNC0487-0111 (the treatment being tested) or Semaglutide (an approved and commonly prescribed treatment used as comparator). Which treatment participants get is decided by chance.
Conditions
- Obesity
- Overweight
- Diabetes Mellitus, Type 2
Interventions
NNC0487-0111Drug
NNC0487-0111 will be administered subcutaneously using PDS290 pre-filled pen-injectors to one of the body parts: thigh, abdomen or upper arm.
SemaglutideDrug
Semaglutide will be administered subcutaneously using PDS290 pre-filled pen-injectors to one of the body parts: thigh, abdomen or upper arm.
Placebo (matched to NNC0487-0111)Drug
Placebo matched to NNC0487-0111 will be administered subcutaneously using pre- filled pen-injectors to one of the body parts: thigh, abdomen or upper arm.
Placebo (matched to semaglutide)Drug
Placebo matched to semaglutide will be administered subcutaneously using pre-filled pen-injectors to one of the body parts: thigh, abdomen or upper arm.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Relative change in body weightTime frame: From baseline (week 0) to week 84
Locations
122 sites in 14 countries. Site status is shown where the registry gives one.
Encore Medical Research LLC
Hollywood, Florida
Optimal Research Sites
Orange City, Florida
Encore Medical Research of Weston
Weston, Florida
Endocrine Research Solutions, Inc
Roswell, Georgia
Elite Clinical Trials
Blackfoot, Idaho
Endo And Metab Cons
Rockville, Maryland
Arcturus Healthcare, PLC.
Troy, Michigan
Velocity Clin Res, Dallas
Dallas, Texas
Consano Clinical Research, LLC
Shavano Park, Texas
Selma Medical Associates
Winchester, Virginia
Centro Médico Privado San Vicente Diabetes
Córdoba, Argentina
Centro de Investigaciones Metabólicas
Capital Federal, Buenos Aires, Argentina
Centro Médico CIMEL
Lanús Este, Buenos Aires, Argentina
Núcleo de Pesquisa Clínica do Rio Grande do Sul Ltda.
Porto Alegre, Rio Grande do Sul, Brazil
i9 Pesquisas Clínicas
Campinas, São Paulo, Brazil
CPQuali Pesquisa Clínica Ltda
São Paulo, São Paulo, Brazil
BR Trials - Ensaios Clínicos e Consultoria Ltda.
São Paulo, São Paulo, Brazil
Dr. Tatyana Metalova - AIPSMCE EOOD
Gotse Delchev, Bulgaria
Medical centre Zdrave 1 OOD
Kozloduy, Bulgaria
UMHAT Pulmed OOD - Pazardzhik, Department of Internal Diseases
Pazardzhik, Bulgaria
MHAT Heart and Brain EAD - Pleven, Endocrinology and Metabolic Diseases
Pleven, Bulgaria
DCC I- Pleven EOOD Endocrinology
Pleven, Bulgaria
MHAT Knyaginya Klementina - Sofia EAD
Sofia, Bulgaria
MHAT Sveta Sofia EOOD, Department of Endocrinology and Metabolic diseases
Sofia, Bulgaria
Acibadem City Clinic UMHAT Tokuda EAD, Endocrinology
Sofia, Bulgaria
USHATE Akad. Ivan Penchev EAD, Second Clinic of Endocrinology
Sofia, Bulgaria
Medical Institute of Ministry of interior
Sofia, Bulgaria
Medical Centre - Clinic Nova EOOD
Varna, Bulgaria
Poliklinika Medikol Zagreb
Grad Zagreb, Croatia
Opca bolnica Karlovac
Karlovac, Croatia
Specijalna Bolnica za medicinsku rehabilitaciju Krapinske Toplice_Endocrinology
Krapinske Toplice, Croatia
Poliklinika SLAVONIJA OSIJEK
Osijek, Croatia
Clinical Hospital Centre Rijeka_Endocrinology
Rijeka, Croatia
General Hospital Dr. Josip Bencevic_Diabetic department
Slavonski Brod, Croatia
Opca bolnica Varazdin_Endocrinology
Varaždin, Croatia
Poliklinika Solmed
Zagreb, Croatia
Herz- und Diabeteszentrum NRW - Bad Oeynhausen
Bad Oeynhausen, Germany
Zentrum für klinische Studien Südbrandenburg GmbH
Elsterwerda, Germany
Praxis am Markt Dr. Becker
Essen, Germany
MVZ im Altstadt-Carree Fulda GmbH - Zentrum für klinische Studien
Fulda, Germany
Showing 40 of 122 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.